Arkolith/Insider Trading/RNA/Form 4

Boyce Sarah

President and CEO, DirectorAvidity Biosciences, Inc. (RNA) · full profile →Form 4 · filed Aug 29, 2025
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.2M
Net Open-Market Flow
-$1.2M
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 28, 2025Option exercise(M)25K$1.24$31K331K
Aug 28, 2025Sell(S)25K$49.39$1.2M306K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 28, 2025Option exercise(M)25K—$01.1M

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001599901-25-000168) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML